Clinical Trial Update: ANAVEX2-73 for Treatment of Early Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trials for ANAVEX2-73 in early Alzheimer's disease completed Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ANAVEX2-73 (blarcamesine)

Snippet

Sponsor: Anavex Life Sciences Corp. | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED